The cancer diagnostics company is hours away from losing funding for its tests through the US Medicare system.
New Zealand proves to be the jewellery brand's most challenged market.
The dual-listed software company's stock value has more-than quadrupled since late 2022.
Listed honey company has reduced 2024 earnings guidance and says 2025 target very unlikely to be met.
Regulators have been coming down hard on casino operators and their breaches of anti-money laundering and counter-terrorism financing legislation.
Nick Grayston will leave the listed retailer, effective immediately, after nearly a decade in charge.
Construction costs and the weak NZD puts paid to plans to replace the 65-year-old Wairākei geothermal plant, but smaller scale plans remain.
Global multinational Nestlé touted as potential buyer.
The re-election of Briscoe chair Rosanne Meo for a final term prompted questions about director independence.
The diversified agri-business has inked a significant deal with the Bostock family.